<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501096</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-A001-111</org_study_id>
    <nct_id>NCT02501096</nct_id>
  </id_info>
  <brief_title>Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in
      participants with selected solid tumors. Phase 1b will determine and confirm the maximum
      tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous
      [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e.
      non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial
      carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion)
      will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase
      1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2015</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD (Phase 1b)</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (SAEs)</measure>
    <time_frame>For each participant, from the first dose till 90 days after the last dose, unless participant starts new anticancer drug then 30 days, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the date of first dose of study drug to the date of first documentation of confirmed disease progression or death (whichever occurs first) or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of first dose of study drug until date of death from any cause or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Stable Disease rate (DSDR)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of lenvatinib</measure>
    <time_frame>0.5-4 hours (hrs), and 6-10 hrs post lenvatinib dose on C1D1, pre-dose, 0.5-4 hrs, and 6-10 hrs post lenvatinib dose on C1D15, and pre-pembrolizumab dose and 2-12 hrs post lenvatinib dose on C2D1. Pre-pembrolizumab dose only on Day 1 of Cycles 3 to 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of lenvatinib</measure>
    <time_frame>0.5-4 hours (hrs), and 6-10 hrs post lenvatinib dose on C1D1, pre-dose, 0.5-4 hrs, and 6-10 hrs post lenvatinib dose on C1D15, and pre-pembrolizumab dose and 2-12 hrs post lenvatinib dose on C2D1. Pre-pembrolizumab dose only on Day 1 of Cycles 3 to 6.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">191</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Lenvatinib + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.</description>
    <arm_group_label>Lenvatinib + pembrolizumab</arm_group_label>
    <other_name>Lenvima, E7080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.</description>
    <arm_group_label>Lenvatinib + pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Phase 1b: Histologically and/or cytologically confirmed metastatic selected solid
             tumor types that have progressed after treatment with approved therapies or for which
             there are no standard effective therapies available. If nivolumab or pembrolizumab is
             an approved therapy for the participant's tumor type, but the participant has not been
             treated with it, the Investigator may enroll the participant in this study. Phase 2:
             Histologically and/or cytologically confirmed metastatic selected solid tumor types
             with 0-2 prior lines of systemic therapy (unless discussed with the sponsor) For the
             non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have
             progressed on or after prior treatment with one anti-PD-1, anti-PD-L1, or anti-PDL2
             agent Selected tumor types of both phases: NSCLC, predominantly clear cell renal cell
             carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the
             head and neck, or melanoma (excluding uveal melanoma)

          2. Life expectancy of 12 weeks or more

          3. Phase 2: Measurable disease meeting the following criteria:

               1. At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a
                  non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a
                  lymph node that is serially measurable according to irRECIST (immune-related
                  RECIST) using computerized tomography/magnetic resonance imaging (CT/MRI)

               2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional
                  therapies such as radiofrequency (RF) ablation must show subsequent evidence of
                  substantial size increase to be deemed a target lesion

          4. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status
             of 0 to 1

          5. Adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP less than or equal to 150/90 mmHg at screening and no
             change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1

          6. Adequate renal function defined as creatinine less than or equal to 1.5 X ULN (upper
             limit of normal) or calculated creatinine clearance greater than or equal to 40 mL/min
             per the Cockcroft and Gault formula with creatinine levels greater than 1.5 X ULN

          7. Adequate bone marrow function:

               1. Absolute neutrophil count (ANC) greater than or equal to 1500/mm3 (greater than
                  or equal to 1.5 X 103/uL)

               2. Platelets greater than or equal to 100,000/mm3 (greater than or equal to 100 X
                  109/L)

               3. Hemoglobin greater than or equal to 9.0 g/dL

          8. Adequate blood coagulation function as evidenced by an International Normalized Ratio
             (INR) less than or equal to 1.5

          9. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the
             ULN and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate
             aminotransferase (AST) less than or equal to 3 X ULN (in the case of liver metastases
             less than or equal to 5 X ULN). In case ALP is greater than 3 X ULN (in the absence of
             liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND
             the participant also is known to have bone metastases, the liver specific ALP must be
             separated from the total and used to assess the liver function instead of the total
             ALP

         10. Males or females age greater than or equal to 18 years at the time of informed consent

         11. Participants with known brain metastases will be eligible if they have completed the
             primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or
             complete surgical resection) and if they have remained clinically stable, asymptomatic
             and off of steroids for at least 28 days before starting study treatment.

         12. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25
             IU/L or equivalent units of beta-human chorionic gonadotropin [Î²-hCG]) at the
             Screening Visit and the Baseline Visit. A pregnancy test needs to be performed within
             72 hours of the first dose of study drug. Females of childbearing potential must agree
             to use a highly effective method of contraception for the entire study period and for
             120 days after study discontinuation, ie

               -  total abstinence (if it is their preferred and usual lifestyle)

               -  an intrauterine device (IUD) or hormone-releasing system (IUS)

               -  a contraceptive implant

               -  an oral contraceptive** (with additional barrier method) OR

               -  have a vasectomized partner with confirmed azoospermia.

             NOTES:

               -  All females will be considered to be of childbearing potential unless they are
                  postmenopausal (amenorrheic for at least 12 consecutive months, in the
                  appropriate age group, and without other known or suspected cause) or have been
                  sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or
                  bilateral oophorectomy, all with surgery at least 1 month before dosing).

               -  Must be on a stable dose of the same oral hormonal contraceptive product for at
                  least 4 weeks before dosing with study drug and for the duration of the study

         13. Male participants who are partners of women of childbearing potential must use a
             condom + spermicide and their female partners if of childbearing potential must use a
             highly effective method of contraception (see methods described in Inclusion Criterion
             #12) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout
             the entire study period, and for 120 days after the last dose of study drug, unless
             the male participants are totally sexually abstinent or have undergone a successful
             vasectomy with confirmed azoospermia or unless the female partners have been
             sterilized surgically or are otherwise proven sterile.

         14. Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol

         15. Archival tumor tissue or a newly obtained biopsy must be available prior to the first
             dose of study drug for biomarker analysis. In the case archival tissue cannot be
             provided, participants with inaccessible tumors for biopsy specimens can be enrolled
             without a biopsy upon consultation and agreement by the sponsor Note: In case of
             submitting unstained cut slides, freshly cut slides should be submitted to the testing
             laboratory within 14 days from when the slides are cut

        Exclusion Criteria:

          1. Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is
             shorter) or any investigational agent within 30 days prior to the first dose of study
             drugs. All acute toxicities related to prior treatments must be resolved to Grade less
             than or equal to 1

          2. Participants must have recovered adequately from any toxicity and/or complications
             from major surgery prior to starting therapy

          3. Participants having greater than 1+ proteinuria on urinalysis will undergo 24-h urine
             collection for quantitative assessment of proteinuria. Participants with urine protein
             greater than or equal to 1 g/24-hour will be ineligible.

          4. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition
             that might affect the absorption of lenvatinib

          5. New York Heart Association congestive heart failure of grade II or above, unstable
             angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia
             associated with significant cardiovascular impairment within the past 6 months

          6. Prolongation of QTc interval to greater than 480 msec

          7. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to
             the first dose of study drug

          8. Active infection (any infection requiring systemic treatment)

          9. Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis
             B, or Hepatitis C

         10. Serious nonhealing wound, ulcer, or bone fracture

         11. Known intolerance to either of the study drugs (or any of the excipients)

         12. History of organ allograft

         13. Biologic response modifiers (eg, granulocyte colony-stimulating factor) within 4 weeks
             before study entry. Chronic erythropoietin therapy is permitted provided that no dose
             adjustments were made within 2 months before first dose of study treatment

         14. Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial

         15. Females who are pregnant or breastfeeding

         16. Excluding the primary tumor leading to enrollment in this study, any other active
             malignancy (except for definitively treated melanoma in-situ, basal or squamous cell
             carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past
             24 months

         17. Prior treatment with lenvatinib or any PD-1, anti-PD-L1, or anti-PD-L2 agent,
             excluding melanoma and NSCLC where prior treatment with one PD-1, anti-PD-L1, or
             anti-PD-L2 agent is allowed

         18. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of study
             treatment. The use of physiologic doses of corticosteroids (up to 7.5mg/d of
             prednisone or equivalent) may be approved after consultation with the sponsor.

         19. No active autoimmune disease that has required systemic treatment in past 2 years (ie,
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement
             therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of
             systemic treatment.

         20. Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

         21. Has received a live-virus vaccination within 30 days of planned treatment start.
             Seasonal flu vaccines that do not contain live virus are permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Oro Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE, Site #1</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE, Site #2</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE, Site #3</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, Site #1</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, Site #2</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC, Site #1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC, Site #2</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC, Site #3</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #1</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #2</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #3</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #1</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #2</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #3</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada, Site #4</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System, Site #1</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System, Site #2</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System, Site #3</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth 12th Ave, Site #1</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Southwest Fort Worth, Site #2</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Garland</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Grapevine</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Plano West</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Waco, Site #1</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Waco, Site #2</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servei d'Oncologia Medica Institut Catala d'Oncologia - Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenvatinib</keyword>
  <keyword>Lenvima</keyword>
  <keyword>E7080</keyword>
  <keyword>Phase 1b/2</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

